In vivo evaluation of CYP2A6 and xanthine oxidase enzyme activities in the Serbian population

European Journal of Clinical Pharmacology

Volumn 66, Issue 6, 2010, Pages 571-578

  Djordjevic, Natasa ^a,b   Carrillo, Juan Antonio ^c   Gervasini, Guillermo ^c   Jankovic, Slobodan ^b   Aklillu, Eleni ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF KRAGUJEVAC   (Serbia)

^c UNIVERSITY OF EXTREMADURA   (Spain)

Author keywords

Caffeine; CYP2A6; Genotype; Phenotype; Serbian; Xanthine oxidase

Indexed keywords

CAFFEINE; CYTOCHROME P450 2A6; XANTHINE OXIDASE; COUMARIN 7 HYDROXYLASE; COUMARIN 7-HYDROXYLASE; UNSPECIFIC MONOOXYGENASE;

ADULT; ARTICLE; CIGARETTE SMOKING; ENZYME ACTIVITY; FEMALE; GENDER; GENE DELETION; GENE FREQUENCY; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; MALE; NORMAL HUMAN; PHARMACOGENETICS; PHENOTYPE; POLYMERASE CHAIN REACTION; POPULATION GENETICS; PRIORITY JOURNAL; SERBIA; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; CAUCASIAN; COMPARATIVE STUDY; ETHNOLOGY; GENETICS; GENOTYPE; METABOLISM; MIDDLE AGED; SMOKING;

ADULT; ARYL HYDROCARBON HYDROXYLASES; CAFFEINE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; SERBIA; SMOKING; XANTHINE OXIDASE;

EID: 77954911831     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0785-6     Document Type: Article

References (44)

1. Oscarson M (2001) Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: implications for interindividual differences in nicotine metabolism. Drug Metab Dispos 29:91-95 (Pubitemid 32112920)
2. Oscarson M, McLellan RA, Gullsten H et al (1999) Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. FEBS Lett 448:105-110
3. Kimura M, Yamazaki H, Fujieda M et al (2005) CYP2A6 is a principal enzyme involved in hydroxylation of 1, 7-dimethylxanthine, a main caffeine metabolite, in humans. Drug Metab Dispos 33:1361-1366
4. Nowell S, Sweeney C, Hammons G et al (2002) CYP2A6 activity determined by caffeine phenotyping: association with colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 11:377-383
5. Hukkanen J, Jacob P III, Benowitz NL (2005) Metabolism and disposition kinetics of nicotine. Pharmacol Rev 57:79-115
6. Benowitz NL, Jacob P III (2000) Effects of cigarette smoking and carbon monoxide on nicotine and cotinine metabolism. Clin Pharmacol Ther 67:653-659
7. Mwenifumbo JC, Sellers EM, Tyndale RF (2007) Nicotine metabolism and CYP2A6 activity in a population of black African descent: impact of gender and light smoking. Drug Alcohol Depen 89:24-33
8. Nakajima M, Fukami T, Yamanaka H et al (2006) Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin Pharmacol Ther 80:282-297
9. Johnstone E, Benowitz N, Cargill A et al (2006) Determinants of the rate of nicotine metabolism and effects on smoking behavior. Clin Pharmacol Ther 80:319-330
10. Benowitz NL, Lessov-Schlaggar CN, Swan GE, Jacob P III (2006) Female sex and oral contraceptive use accelerate nicotine metabolism. Clin Pharmacol Ther 79:480-488
11. Begas E, Kouvaras E, Tsakalof A et al (2007) In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios. Biomed Chromatogr 21:190-200
12. Krul C, Hageman G (1998) Analysis of urinary caffeine metabolites to assess biotransformation enzyme activities by reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 709:27-34
13. Guerciolini R, Szumlanski C, Weinshilboum RM (1991) Human liver xanthine oxidase: nature and extent of individual variation. Clin Pharmacol Ther 50:663-672
14. Relling MV, Lin JS, Ayers GD, Evans WE (1992) Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin Pharmacol Ther 52:643-658
15. Garattini E,Mendel R, RomaoMJ et al (2003)Mammalianmolybdoflavoenzymes, an expanding family of proteins: structure, genetics, regulation, function and pathophysiology. Biochem J 372:15-32
16. Pritsos CA (2000) Cellular distribution, metabolism and regulation of the xanthine oxidoreductase enzyme system. Chem Biol Interact 129:195-208
17. Harrison R (2002) Structure and function of xanthine oxidoreductase: where are we now? Free Radic Biol Med 33:774-797
18. Carrillo JA, Benitez J (1994) Caffeine metabolism in a healthy Spanish population: N-acetylator phenotype and oxidation pathways. Clin Pharmacol Ther 55:293-304
19. Aklillu E, Carrillo JA, Makonnen E et al (2003) Xanthine oxidase activity is influenced by environmental factors in Ethiopians. Eur J Clin Pharmacol 59:533-536
20. Kudo M, Moteki T, Sasaki T et al (2008) Functional characterization of human xanthine oxidase allelic variants. Pharmacogenet Genomics 18:243-251
21. Kalow W, Tang BK (1991) Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther 50:508-519
22. Rasmussen BB, Brosen K (1996) Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans. Ther Drug Monit 18:254-262
23. Jetter A, Kinzig M, Rodamer M et al (2009) Phenotyping of Nacetyltransferase type 2 and xanthine oxidase with caffeine: when should urine samples be collected? Eur J Clin Pharmacol 65 (4):411-417
24. Ghotbi R, Christensen M, Roh HK et al (2007) Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol 63:537-546
25. Djordjevic N, Ghotbi R, Bertilsson L et al (2008) Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes. Eur J Clin Pharmacol 64:381-385
26. Fukami T, Nakajima M, Yamanaka H et al (2007) A novel duplication type of CYP2A6 gene in African-American population. Drug Metab Dispos 35:515-520
27. Rao Y, Hoffmann E, Zia M et al (2000) Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. Mol Pharmacol 58:747-755
28. Carrillo JA, Christensen M, Ramos SI et al (2000) Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine. Ther Drug Monit 22:409-417
29. Yoshida R, Nakajima M, Watanabe Y et al (2002) Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism. Br J Clin Pharmacol 54:511-517
30. Maurice M, Emiliani S, Dalet-Beluche I et al (1991) Isolation and characterization of a cytochrome P450 of the IIA subfamily from human liver microsomes. Eur J Biochem 200:511-517
31. Shimada T, Yamazaki H, Guengerich FP (1996) Ethnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P4502A6 in liver microsomes of Japanese and Caucasian populations. Xenobiotica 26:395-403
32. Pelkonen O, Rautio A, Raunio H, Pasanen M (2000) CYP2A6: a human coumarin 7-hydroxylase. Toxicology 144:139-147
33. Vasconcelos GM, Struchiner CJ, Suarez-Kurtz G (2005) CYP2A6 genetic polymorphisms and correlation with smoking status in Brazilians. Pharmacogenomics J 5:42-48
34. Tyndale RF, Sellers EM (2002) Genetic variation in CYP2A6- mediated nicotine metabolism alters smoking behavior. Ther Drug Monit 24:163-171
35. Oscarson M, McLellan RA, Gullsten H et al (1999) Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism. FEBS Lett 460:321-327
36. Gambier N, Batt A-M, Marie B et al (2005) Association of CYP2A6*1B genetic variant with the amount of smoking in French adults from the Stanislas cohort. Pharmacogenom J 5:271-275
37. Parsons WD, Neims AH (1978) Effect of smoking on caffeine clearance. Clin Pharmacol Ther 24:40-45
38. Djordjevic N (2008) Pharmacogenetics of drug metabolizing enzymes CYP1A2 and CYP2A6 in Serbian population. In Edition Kragujevac: University of Kragujevac>
39. Hakooz NM (2009) Caffeine metabolic ratios for the in vivo evaluation of CYP1A2, N-acetyltransferase 2, xanthine oxidase and CYP2A6 enzymatic activities. Curr Drug Metab 10:329-338
40. Campbell ME, Grant DM, Inaba T, Kalow W (1987) Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome (s) P-450 in human liver microsomes. Drug Metab Dispos 15:237-249
41. Grant DM, Campbell ME, Tang BK, Kalow W (1987) Biotransformation of caffeine by microsomes from human liver. Kinetics and inhibition studies. Biochem Pharmacol 36:1251-1260
42. Benowitz NL, Swan GE, Jacob P III et al (2006) CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. Clin Pharmacol Ther 80:457-467
43. Chung WG, Kang JH, Park CS et al (2000) Effect of age and smoking on in vivo CYP1A2, flavin-containing monooxygenase, and xanthine oxidase activities in Koreans: determination by caffeine metabolism. Clin Pharmacol Ther 67:258-266
44. Saruwatari J, Nakagawa K, Shindo J et al (2002) A population phenotyping study of three drug-metabolizing enzymes in Kyushu, Japan, with use of the caffeine test. Clin Pharmacol Ther 72:200-208